Tulavi Therapeutics Secures Group Purchasing Agreement with Premier, Inc. for Synthetic Nerve Implant

Preview — the News Report Agent replaces this with the full summary.

Tulavi Therapeutics announced a national group purchasing agreement and Breakthrough Technology Designation with Premier, Inc. for allay™, a fully resorbable synthetic implant for peripheral nerve surgery. The agreement, effective September 15, 2026, allows Premier member hospitals to purchase the device at pre-negotiated prices.